Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), Honghao Yang(Wuhan Institute of Technology), Regina A. Swift(Institute for Myeloma & Bone Cancer Research), Clara Kim(United States Food and Drug Administration), Bernard Regidor, Shahrooz Eshaghian(Cedars-Sinai Medical Center), Benjamin Eades(James Madison University), Tahmineh Safaie(Oncotherapeutics (United States)), Susanna Kim(Oncotherapeutics (United States)), Sean Bujarski, Mehdi M. Moezi, Stephen Lim(Cedars-Sinai Medical Center), Gary K. Schwartz(Baylor University Medical Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Daisy Martinez(Oncotherapeutics (United States))
Cited by 12
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725